Medindia

X

China Shenghuo to Resume Trading on NYSE Alternext US LLC

Wednesday, December 10, 2008 General News J E 4
Advertisement
KUNMING, China, Dec. 9 China ShenghuoPharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China Shenghuo" orthe "Company"), today announced that the Company's shares would resume tradingon NYSE Alternext US LLC ("NYSE Alternext US" or the "Exchange") at the openof business on Tuesday, December 9th. The Company's shares will continue totrade under the symbol "KUN."

"We are delighted that the Exchange has decided to allow our shares toresume trading," said Mr. Gui Hua Lan, Chief Executive Officer of ChinaShenghuo. "The relisting of our shares marks a major milestone for the Companyand it offers a measure of reassurance to both our retail and institutionalinvestors that we have succeeded in putting a very challenging period in theCompany's history behind us."

About China Shenghuo

Founded in 1995, China Shenghuo is a specialty pharmaceutical company thatfocuses on the research, development, manufacture and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmeticproducts. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co.,Ltd., it owns thirty SFDA (State Food and Drug Administration) approvedmedicines, including the flagship product Xuesaitong Soft Capsules, which hasalready been listed in the Insurance Catalogue. At present, China Shenghuoincorporates a sales network of agencies and representatives throughout China,which markets Sanchi-based traditional Chinese medicine to hospitals and drugstores as prescription and OTC drugs primarily for the treatment ofcardiovascular, cerebrovascular and peptic ulcer disease. The Company alsoexports medicinal products to Asian countries such as Indonesia, Russia andKyrgyzstan. For more information, please visit http://www.shenghuo.com.cn .

Safe Harbor Statement

This press release may contain certain "forward-looking statements," asdefined in the United States Private Securities Litigation Reform Act of 1995,that involve a number of risks and uncertainties. There can be no assurancethat such statements will prove to be accurate, and the actual results andfuture events could differ materially from management's current expectations.Such factors include, but are not limited to, risks of litigation andgovernmental or other regulatory inquiry or proceedings arising out of orrelated to any of the matters described in recent press releases, includingarising out of the restatement of the Company's financial statements; theCompany's continuing ability to satisfy any requirements which may beprescribed by the Exchange for continued listing on the Exchange; potentialadverse effects to the Company's financial condition, results of operations orprospects as a result of possible changes to or restatements of prior periodfinancial statements; risks arising from potential weaknesses or deficienciesin the Company's internal control over financial reporting; the Company'sreliance on one supplier for Sanchi; the possible effect of adverse publicityon the Company's business, including possible contract cancellation; theCompany's ability to develop and market new products; the Company's ability toestablish and maintain a strong brand; the Company's continued ability toobtain and maintain all certificates, permits and licenses required to openand operate retail specialty counters to offer its cosmetic products andconduct business in China; protection of the Company's intellectual propertyrights; market acceptance of the Company's products; changes in the laws ofthe People's Republic of China that affect the Company's operations; cost tothe Company of complying with current and future governmental regulations; theimpact of any changes in governmental regulations on the Company's operations;general economic conditions; and other factors detailed from time to time inthe Company's filings with the United States Securities and ExchangeCommission and other regulatory authorities. The Company undertakes noobligation to publicly update or revise any forward-looking statements,whether as a result of new information, future events or otherwise.For more information, please contact: China Shenghuo Pharmaceutical Holdings, Inc. Mr. Changhua Mu Securities Affairs Representative Tel: +86-871-728-2698 Email: c.mu@chinashenghuo.net Grayling Global Eddie Cheung Investor Relations Tel: +1-646-284-9414 Email: echeung@hfgcg.com

SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Hooper Holmes Appoints Marcus Mears President of U...
S
STOP Obesity Alliance Releases Obesity GPS to Chan...